Australia's most trusted source of pharma news
Friday, 29 April 2016
Lost Your Access?
PBAC to vet biosimilar threat on Pfizer's Enbrel
The PBAC's July agenda shows Pfizer's $179m Enbrel is facing a biosimilar threat, while infectious diseases rule among the major submissions.
TGA signals approval of seven new meds
Seven new chemical entities, including
, BI's antidote for
, and those that make up MSD's hep C medicine
appear to be close to Australian approval.
Five-days-after contraceptive launched
A shake-up of the emergency contraceptive pill market is on the horizon with MS Health launching a new five-day emergency contraceptive pill -
Cut Lyrica dose says pain specialist
A pain specialist has called for the starting dose of Pfizer's blockbuster neuropathic pain medicine
to be lowered to as little as 25mg.
Positive Champix news for Pfizer
Study finds no significant increase in neuropsychiatric adverse events in those taking Champix.
Staff bonuses on the rise in pharma
Australian pharma companies are increasingly linking staff salaries to company and/or personal incentive-based bonuses but is work/life balance taking a back seat?
Pharma's female employees not equal yet
Women in the Australian pharmaceutical industry continue to earn less than men but are starting to rise to the top pay ranks in specialist roles rather than through general management.
March PBAC disappoints on many fronts
Many highly anticipated listings received the thumbs down at the March meeting of the PBAC, although it was not all bad news.
Senators slam pharma in tax avoidance report
Pharmacos and some of the individuals who run them have come in for savage criticism in the Senate's latest report on alleged tax avoidance by multinational companies.
Pay rates a rising issue in pharma
People working in Australian pharmaceutical companies are less satisfied with their pay packets now than they were 18 months ago and more likely to consider themselves underpaid.
Heart Foundation backs Entresto despite PBAC
Despite the PBAC rejecting Novartis's breakthrough heart medicine
, the Heart Foundation remains positive that it will be PBS listed.
TGA loses out to cigarette maker
A subsidiary of British American Tobacco has forced the TGA to reconsider a decision to reject its attempt to register a nicotine inhaler as an OTC medicine.
Bayer surges on Xarelto growth
Blood thinner Xarelto has led Bayer to a 12.2% rise in first quarter prescription medicine sales allowing it to beat income forecasts for the period.
Janssen's Olysio listing hangs in the balance
The PBAC's recent positive recommendation for the simplification of Janssen's hep C treatment
listing came with a sting in its tail.
Big boost for real time script tracking
The PSA and the Pharmacy Guild have welcomed a Victorian Government funding commitment of around $30 million for the implementation of a Real Time Prescription Monitoring (RTPM) system.
July PBAC reveals short but significant agenda
The next meeting of the PBAC has fewer submissions to decide on than has been the case recently but many concern significant innovative medicines.
Employee benefits: are you on par?
Benefits from car allowances to special leave are now a key part of packages in pharma. Our survey reveals the trends in what companies are offering.
Sanofi registers new sevelamer brands
Sanofi's Genzyme division has registered two new brands of $12m hyperphosphataemia treatment Renagel (sevelamer).
Lean March for PBAC positives
The full results of the March 2016 PBAC meeting show just under half of major submissions picking up a positive recommendation.
Pharma-govt collaboration the only way forward
MSD's Zarli French, winner of this year's Pat Clear award, stresses the importance of collaboration as she reflects on her 30 years in pharma.
Events & Conferences
© 2003 - 2016 Lush Media
Pharma in Focus
Jolly Good Design